TY - JOUR JO - Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii SN - 1642-395X VL - 35 IS - 6 PY - 2018 ID - Czarny2018 TI - Cutaneous mastocytosis treatment: strategies, limitations and perspectives AB - Mastocytosis is a rare myeloproliferative disease, characterized by excessive proliferation and accumulation of mast cells in the tissues. In cutaneous mastocytosis (CM), mast cells infiltration is limited to the skin, whereas in systemic mastocytosis (SM) internal organs are involved. The first-line treatment in CM is antimediator therapy (mainly H1 and H2 antihistamines) and short-term topical corticosteroids. Phototherapy is the second-line therapy which may be considered when antihistamines do not produce the expected improvement. New therapeutic options include omalizumab and KIT-targeting agents. Although the disappearance of skin lesions has been reported as a result of cytoreductive therapies in SM, the use of potentially toxic drugs in CM is not recommended. In all adults with mastocytosis and in pediatric patients with severe CM, a persistently elevated serum tryptase level and anaphylaxis in medical history, equipping with epinephrine autoinjector for use in case of anaphylaxis is recommended. AU - Czarny, Justyna AU - Lange, Magdalena AU - Ługowska-Umer, Hanna AU - Nowicki, Roman SP - 541 EP - 545 DA - 2018 DO - 10.5114/ada.2018.77605 UR - http://dx.doi.org/10.5114/ada.2018.77605 ER -